Researchers complete the first epigenome in Europe

A study led by Manel Esteller, director of the Epigenetics and Cancer Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), professor of genetics at the University of Barcelona and ICREA researcher, has completed the first epigenome in Europe. The finding is published in the latest issue of the international scientific journal Epigenetics.

The genome of all cells in the human body is the same for all of them, regardless their aspect and functions. Therefore, genome cannot fully explain the activity of tissues and organs and their disorders in complex diseases like cancer. It takes a further explanation. Part of this explanation is provided by epigenetics, a field of biology that studies the activity of DNA that does not involve changes in its sequence. That is, if genetics is the alphabet, epigenetics is the spelling that guides the activity of our cells.

Methylation

Epigenetics refers to in our and proteins that regulate it. The best-known epigenetic mark is the methylation, the addition of a methyl chemical group (-CH3) in our DNA. The epigenome consists of all the epigenetic marks of a living being.

The authors of the study have completed the for all brands of methylation of DNA from of two girls: a healthy one and a patient suffering from a called Immunodeficiency, Centromere instability and Facial anomalies syndrome (ICF). This disease is caused by a mutation in a gene that causes the addition of a methyl chemical group in its DNA.

The analysis performed by the researchers reveals that the patient has an epigenomic defect that causes fragility of chromosomes, which thus can easily be broken. In addition, the study shows that the patient has a wrong epigenetic control of many genes related to the response against infection, which causes a severe .

The study coordinator, Manel Esteller, emphasizes that due to this study, "we now know what happens in this type of rare diseases and we can start thinking about strategies for new treatments based on this knowledge."

Dr. Esteller is an international leader in the field of epigenetics. His work has been crucial to show that all human tumours have in common a specific chemical alteration: the hypermethylation of tumour suppressor genes. Since 2008 is the director of the Epigenetics and Cancer Biology Program at IDIBELL.

More information: Heyn H, Vidal E, Sayols S, Sanchez-Mut JV, Moran S, Medina I, Sandoval J, Simó-Riudalbas L, Szczesna K, Huertas D, Gatto S, Matarazzo MR, Dopazo J, Esteller M. Whole-genome bisulfite DNA sequencing of a DNMT3B mutant patient. Epigenetics, June 1, 2012.

add to favorites email to friend print save as pdf

Related Stories

Why cancer cells change their appearance?

Sep 02, 2011

Like snakes, tumour cells shed their skin. Cancer is not a static disease but during its development the disease accumulates changes to evade natural defences adapting to new environmental circumstances, protecting against ...

Recommended for you

Infant failure to thrive linked to lysosome dysfunction

Jan 27, 2015

Neonatal intestinal disorders that prevent infants from getting the nutrients they need may be caused by defects in the lysosomal system that occur before weaning, according to a new Northwestern Medicine ...

Gene may open door for improved keloid, scar treatment

Jan 23, 2015

Researchers at Henry Ford Hospital in Detroit have identified a gene that may offer a better understanding of how keloid scars develop and potentially open the door to improved treatment for the often painful, ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.